Daphnetin

Phase 3Small molecule

FFirst People's Hospital of Shenyang

Daphnetin is one of 79 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

SurgeryRecruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

SurgeryPhase 3

Recruiting

Competition

Competitive Landscape

72 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Marinol

Intropin

Brintellix

Avandia

Epidiolex

Bendopa

MMerz North America, Inc.

Approved

1 7

Coumadin

AAbbott

Approved

1 8

Pradaxa

Boehringer Ingelheim

Approved

1 9

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Cerebrovascular Disorders

NCT06507488

Clinical

Trials by Indication[1]

Surgery1 trial

Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery

Recruiting·TThe First Hospital of Jilin University·Phase 4·NCT06329167·100 enrolled

Cerebrovascular Disorders1 trial

Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study

Recruiting·FFirst People's Hospital of Shenyang·Preclinical·NCT06507488·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Daphnetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daphnetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daphnetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First People's Hospital of Shenyang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFirst People's Hospital of Shenyang

Daphnetin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Surgery1 trial

Cerebrovascular Disorders1 trial

References

Drug Info

Quick Facts

Related News